Revvity (RVTY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Revvity

NYSE•Healthcare•Diagnostics & Research

$146.73+1.00(0.01%)After hours

Market Cap

$15.86B

P/E

66.8x

P/S

5.4x

P/B

2.2x

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

How this company scores

GoodMetricSide Score: 63/100

Strongest: Cash & Earnings Quality (23/25); weakest: Growth (11/25).

Profitability11/25

Growth11/25

Balance Sheet & Red Flags18/25

Cash & Earnings Quality23/25

Strengths

Low leverageCash-backed earningsConsistent free cash flowImproving leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 66.8x5y range 17.5x – 85.5x

Currently above its 20-quarter median.

P/S · 5.4x5y range 3.3x – 6.8x

Currently near its 20-quarter median.

P/B · 2.2x5y range 1.3x – 3.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 9.2% — watch for continued compression, which may signal competitive or cost pressure.

Price & Volume

Market Cap $15.86B

Metrics at a Glance

as of July 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.91B
Q. Revenue: $729.69M
TTM EBITDA: $771.08M
TTM Op. Income: $358.85M
Q. Op. Income: $89.32M
TTM Net Income: $237.55M
Q. Net Income: $51.82M
EPS: $0.47
Shares Out.: $110.26M

$2.91B in TTM revenue grew 4.1% YoY, reaching $729.69M last quarter. TTM EBITDA of $771.08M and TTM operating income of $358.85M show growth is flowing through to the bottom line. TTM net income of $237.55M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 57.1%
EBITDA Margin: 26.2%
Op. Margin: 12.2%
Net Margin: 7.1%

Op. margin of 12.2% is down 0.4% YoY — costs are rising relative to revenue. Net margin at 7.1% and gross margin of 57.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 3% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 66.8x
P/S Ratio: 5.4x
P/B Ratio: 2.2x

At 66.8x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 5.4x and P/B of 2.2x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is up 66% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $12.05B
Cash: $1.02B
Long-Term Debt: $2.63B
Book Value: $7.23B
D/E Ratio: 0.4
Debt/EBITDA: 13.8

With $12.05B in assets and $2.63B in long-term debt, D/E is 0.4and book value is $7.23B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 14% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $191.94M
TTM Free Cash Flow: $568.85M
FCF Margin: 19.5%
FCF / Net Income: 2.4

TTM FCF of $568.85M on $191.94M in operating cash flow. The FCF / Net Income ratio of 2.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 10% — an improving trend.